California State Teachers Retirement System cut its stake in shares of Dermira Inc (NASDAQ:DERM) by 9.7% in the third quarter, HoldingsChannel.com reports. The firm owned 60,958 shares of the biopharmaceutical company’s stock after selling 6,560 shares during the quarter. California State Teachers Retirement System’s holdings in Dermira were worth $1,646,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in DERM. BNP Paribas Arbitrage SA grew its stake in shares of Dermira by 2,220.7% during the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 3,975 shares during the period. Quantbot Technologies LP grew its stake in shares of Dermira by 75.4% during the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 2,309 shares during the period. SG Americas Securities LLC grew its stake in shares of Dermira by 66.8% during the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,203 shares during the period. Legal & General Group Plc grew its stake in shares of Dermira by 40.9% during the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 2,803 shares during the period. Finally, Ardsley Advisory Partners acquired a new stake in shares of Dermira during the second quarter worth $291,000. 99.47% of the stock is owned by institutional investors and hedge funds.

Dermira Inc (NASDAQ DERM) opened at $28.21 on Friday. Dermira Inc has a 52 week low of $21.35 and a 52 week high of $38.75. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $1,190.00, a PE ratio of -4.53 and a beta of 0.80.

Dermira (NASDAQ:DERM) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.09). Dermira had a negative net margin of 992.18% and a negative return on equity of 41.22%. equities research analysts predict that Dermira Inc will post -7.36 EPS for the current year.

DERM has been the subject of a number of analyst reports. Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $45.00 target price on shares of Dermira in a research note on Tuesday, September 26th. Leerink Swann reissued an “outperform” rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, Guggenheim reissued a “buy” rating and issued a $30.00 target price on shares of Dermira in a research note on Thursday, December 14th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. Dermira presently has a consensus rating of “Hold” and an average price target of $42.17.

In other news, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Christopher M. Griffith sold 18,458 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total value of $499,288.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 36,258 shares of company stock valued at $985,873. Insiders own 13.30% of the company’s stock.

WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/21/california-state-teachers-retirement-system-sells-6560-shares-of-dermira-inc-derm.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.